Get a glimpse of what’s happening at the 2026 ASCO GI meeting in San Francisco, California.

Josh Meyer, MD: Nonoperative Management of Gastroesophageal Cancer: Assessing Esophageal Adenocarcinoma that Shows a Clinical Complete Response

Josh Meyer, MD, of Fox Chase Cancer Center in Philadelphia, Pennsylvania, noted that while patients with gastroesophageal cancer who undergo the CROSS regimen generally do well with surgery, an esophagectomy is a high-risk procedure with an approximately 50% significant morbidity rate, and that oncologists should consider nonsurgical options as well.

MORE ASCO GI 2026 CONFERENCE COVERAGE:

Nilo Azad, MD: The Treatment of Unresectable Colorectal Metastases with Local Regional Therapies

Nilo Azad, MD, a medical oncologist at Johns Hopkins, highlighted the key topics from her session, which focused on reviewing existing data for different modalities of local regional therapy: interventional radiology approaches, radiation oncology–based approaches, and surgical approaches.

Geoffrey Ku, MD: The Treatment of Oligometastatic Disease in Esophagogastric Cancer

Geoffrey Ku, MD, of the Memorial Sloan Kettering Cancer Center, said these patients require careful management, discussion in a multidisciplinary setting, and the best systemic therapy before any consideration of local therapy options.

Daniela Molena, MD: Prioritizing Surgery Right After Treatment for Patients with Esophageal Carcinoma

Daniela Molena, MD, of the Memorial Sloan Kettering Cancer Center, argues that healthcare professionals don't have the tools yet to know when a clinical complete response is also a pathological complete response, and until then, surgery is usually the best option for patients with esophageal carcinoma.